TheraRadar
← Back
Data updated: Jun 28, 2026

LABS JUVISE

Pharma

LABS JUVISE is a pharmaceutical company focused on Infectious Disease, Gastroenterology.

2006
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

LABS JUVISE's Key Drugs

LABS JUVISE's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

LABS JUVISE's Recent FDA Approvals

New NDA/BLA approvals for LABS JUVISE over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

LABS JUVISE's Therapeutic Areas

LABS JUVISE's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Gastroenterology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 50%
1 drugs
Gastroenterology 50%
1 drugs

LABS JUVISE's Top Competitors

LABS JUVISE's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and APOTHECON. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

LABS JUVISE Pipeline Snapshot

Active clinical trials for LABS JUVISE across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Infectious Disease pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling